ZEUS A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease chronic kidney disease and inflammation

Go Back to All Clinical Trials

ZEUS A research study to look at how ziltivekimab works compared to placebo in people with cardiovascular disease chronic kidney disease and inflammation

Brief description of study

The purpose of this study is to see if the new study medicine, ziltivekimab, can be used to treat people with cardiovascular disease, chronic kidney disease and inflammation. The ZEUS study will see if ziltivekimab can reduce the risk of having cardiovascular events (for example heart attack and stroke). The term cardiovascular disease refers to several conditions that affect your heart and blood vessels. These conditions include myocardial infarction (also known as heart attack), stroke (also known as brain attack) and peripheral arterial disease (also known as poor circulation). Ziltivekimab is an antibody, which is designed to block the action of IL 6. In that way, ziltivekimab can help the body to avoid more inflammation.

Clinical Study Identifier: s22-00218

ClinicalTrials.gov Identifier: NCT05021835

Principal Investigator: Michael Seth Garshick.

Other Investigator: Howard Weintraub.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies